Companies
ASND
Ascendis Pharma A/S
$229.38-6.52%1Y
ASND · daily close · illustrative · 0 catalysts marked
Pipeline
Phase 2Advanced Solid Tumor
Phase 2Locally Advanced Solid Tumor
Phase 2Metastatic Solid Tumor
Phase 2Platinum-resistant Ovarian Cancer
Phase 2Post Anti-PD-1 Melanoma
Phase 22L+ Cervical Cancer
Phase 2Neoadjuvant Melanoma
Phase 2Neoadjuvant Non-Small Cell Lung Cancer
Phase 2Post Anti-PD-(L)1 Non-Small Cell Lung Cancer
Phase 2Post Anti-PD-(L)1 Small Cell Lung Cancer
Phase 2Third Line or Later (3L+) HER2+ Breast Cancer
Phase 2Second or Third Line (2L/3L) Cervical Cancer
Phase 2Turner Syndrome
Phase 2Achondroplasia
Phase 2Neoadjuvant Non-Small Cell Lung Cancer
Phase 2Advanced Solid Tumor
Phase 2Locally Advanced Solid Tumor
Phase 2Metastatic Solid Tumor
Phase 2Platinum-resistant Ovarian Cancer
Phase 2Post Anti-PD-1 Melanoma
Phase 22L+ Cervical Cancer
Phase 2Neoadjuvant Melanoma
Phase 2Post Anti-PD-(L)1 Non-Small Cell Lung Cancer
Phase 2Post Anti-PD-(L)1 Small Cell Lung Cancer
Phase 2Third Line or Later (3L+) HER2+ Breast Cancer
Phase 2Second or Third Line (2L/3L) Cervical Cancer
Phase 2Turner Syndrome
Phase 2Advanced Solid Tumor
Phase 2Locally Advanced Solid Tumor
Phase 2Metastatic Solid Tumor
Phase 2Platinum-resistant Ovarian Cancer
Phase 2Post Anti-PD-1 Melanoma
Phase 22L+ Cervical Cancer
Phase 2Neoadjuvant Melanoma
Phase 2Neoadjuvant Non-Small Cell Lung Cancer
Phase 2Post Anti-PD-(L)1 Non-Small Cell Lung Cancer
Phase 2Post Anti-PD-(L)1 Small Cell Lung Cancer
Phase 2Third Line or Later (3L+) HER2+ Breast Cancer
Phase 2Second or Third Line (2L/3L) Cervical Cancer
Phase 2Advanced Solid Tumor
Phase 2Locally Advanced Solid Tumor
Phase 2Metastatic Solid Tumor
Phase 2Platinum-resistant Ovarian Cancer
Phase 2Post Anti-PD-1 Melanoma
Phase 22L+ Cervical Cancer
Phase 2Neoadjuvant Melanoma
Phase 2Neoadjuvant Non-Small Cell Lung Cancer
Phase 2Post Anti-PD-(L)1 Non-Small Cell Lung Cancer
Phase 2Post Anti-PD-(L)1 Small Cell Lung Cancer
Phase 2Third Line or Later (3L+) HER2+ Breast Cancer
Phase 2Second or Third Line (2L/3L) Cervical Cancer
Phase 2Advanced Solid Tumor
Phase 2Locally Advanced Solid Tumor
Phase 2Metastatic Solid Tumor
Phase 2Platinum-resistant Ovarian Cancer
Phase 2Post Anti-PD-1 Melanoma
Phase 22L+ Cervical Cancer
Phase 2Neoadjuvant Melanoma
Phase 2Neoadjuvant Non-Small Cell Lung Cancer
Phase 2Post Anti-PD-(L)1 Non-Small Cell Lung Cancer
Phase 2Post Anti-PD-(L)1 Small Cell Lung Cancer
Phase 2Third Line or Later (3L+) HER2+ Breast Cancer
Phase 2Second or Third Line (2L/3L) Cervical Cancer
Phase 2Advanced Solid Tumor
Phase 2Locally Advanced Solid Tumor
Phase 2Metastatic Solid Tumor
Phase 2Platinum-resistant Ovarian Cancer
Phase 2Post Anti-PD-1 Melanoma
Phase 22L+ Cervical Cancer
Phase 2Neoadjuvant Melanoma
Phase 2Neoadjuvant Non-Small Cell Lung Cancer
Phase 2Post Anti-PD-(L)1 Non-Small Cell Lung Cancer
Phase 2Post Anti-PD-(L)1 Small Cell Lung Cancer
Phase 2Third Line or Later (3L+) HER2+ Breast Cancer
Phase 2Second or Third Line (2L/3L) Cervical Cancer
Catalyst Calendar
No catalyst events on record for yet. Check back after the next daily ingest.